Malignant Reproductive System Neoplasm

subtype

Identifier: CI-CAN-00001172
Entity page: /cancer/malignant-reproductive-system-neoplasm ↗
Edges: 12,119

Neighbours: 15 genes22 drugs10 trials
Drawn: 47 of 47 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Reproductive System Neoplasm approved for …APPROVED_FORderived15 of 99show all (up to 200)
← approved for	Etoposidesmall molecule FDA (US) · approved · 2026-02-13 · Refractory testicular cancer	—	approved	Malignant Testicular Neoplasm	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

BRCA1 Mutation OlaparibFDA US 2017-08-1751 active / 116 trials
Curatedlevel Asensitivity· support 7civicObservedBRCA1 altered in 1.1% (20 / 1,882 cases, largest of 2 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Ovarian Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm +1
BRCA2 Mutation OlaparibFDA US 2017-08-1751 active / 116 trials
Curatedlevel Asensitivity· support 6civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 14 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Ovarian Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm +1
BRCA2 Mutation RucaparibFDA US 2016-12-194 active / 26 trials
Curatedlevel Asensitivity· support 5civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 14 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Malignant Ovarian Neoplasm, Castration-Resistant Prostate Carcinoma
BRCA1 Mutation RucaparibFDA US 2016-12-194 active / 26 trials
Curatedlevel Asensitivity· support 5civicObservedBRCA1 altered in 1.1% (20 / 1,882 cases, largest of 2 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Malignant Ovarian Neoplasm, Castration-Resistant Prostate Carcinoma
ATM Mutation OlaparibFDA US 2017-08-1751 active / 116 trials
Curatedlevel Asensitivity· support 2civicObservedATM altered in 4.2% (86 / 2,069 cases, largest of 16 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Prostate Neoplasm, Castration-Resistant Prostate Carcinoma
CDK12 Mutation OlaparibFDA US 2017-08-1751 active / 116 trials
Curatedlevel Asensitivity· support 1civicObservedCDK12 altered in 5.7% (118 / 2,069 cases, largest of 9 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
CHEK2 mutation OlaparibFDA US 2017-08-1751 active / 116 trials
Curatedlevel Asensitivity· support 1civicObservedCHEK2 altered in 4.2% (21 / 499 cases)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BARD1 Mutation OlaparibFDA US 2017-08-1751 active / 116 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BARD1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Malignant Reproductive System Neoplasm altered in cohorts of …ALTERED_INderived15 of 709show all (up to 200)
← altered in cohorts of	TNIK 228 / 306 cases (75 %) · ssm · TCGA-CESC · largest of 2 cohorts	—	—	Cervical Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	BCHE 226 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CLDN16 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts	—	—	Cervical Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	FNDC3B 226 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SLC7A14 226 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SPATA16 226 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TBL1XR1 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts	—	—	Cervical Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	ZBBX 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts	—	—	Cervical Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	ABCC5 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts	—	—	Cervical Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	ACTRT3 225 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A5 225 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts	—	—	Cervical Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	BCL6 225 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CLDN11 225 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LPP 225 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRC31 225 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →

Malignant Reproductive System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 320show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 415 trials (88 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	415	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 388 trials (91 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	388	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 286 trials (49 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	286	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 255 trials (62 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	255	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 220 trials (80 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	220	Observed	clinicaltrials	graph →
→ investigated in trials for	Enzalutamidesmall molecule 201 trials (70 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	201	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 194 trials (45 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	194	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 167 trials (78 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	167	Observed	clinicaltrials	graph →
→ investigated in trials for	Leuprolideother 131 trials (30 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	131	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 128 trials (34 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	128	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 116 trials (51 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	116	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 115 trials (25 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	115	Observed	clinicaltrials	graph →
→ investigated in trials for	Abiraterone Acetatesmall molecule 107 trials (39 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Bicalutamidesmall molecule 107 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 101 trials (13 active) · roll-up of the cancer and its descendants	—	—	Malignant Reproductive System Neoplasm	101	Observed	clinicaltrials	graph →

Malignant Reproductive System Neoplasm studied in …STUDIED_INderived10 of 10,991show all (up to 200)
→ studied in	NCT01230866Phase 3 · active not recruiting Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01242072Phase 1 · completed Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)	—	—	Malignant Testicular Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01492972Phase 3 · recruiting Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)	—	—	Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)	—	—	Cervical Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 10,991 trials mapped (3,193 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 10,991 trials mapped (3,193 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 10,991 trials mapped (3,193 active)	—	—	Penile Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05051722recruiting Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer · condition mapped CURATED_EXACT · 10,991 trials mapped (3,193 active)	—	—	Malignant Cervical Neoplasm	1	Observed	clinicaltrials	graph →